Table VIII.—Data on Papanicolaou smears during use of oral contraceptives

Reference	Compound	Number women treated	Total cycles studied	Number smears treated women	Number smears control women	Number smears positive	Number positive expected
Pincus, 1959 Goldzieher et al., 1962 Rice-Wray et al., 1962 Rice-Wray et al., 1963	Enovid Ortho-Novum do Enovid	830 210 364 2,040	8, 133 6, 232 6, 062 3 22, 948	(1) (2) (2) (2)		0 0 0	11. 8
Pincus, 1961 Tyler, 1961	doEnovid, Ortho-Novum	1,004	* 33, 132		411, 664 	Positive smears in treated women (percent)	Positive smears in control women (percent) 1. 1 . 6
Tyler, 1964	Enovid, Ortho-Novum and other.			6, 746	2, 510	. 77	1. 23

¹ Number not stated.

From Drill, V.A., Pacific Medical and Surgical, 73: November-December 1964.

Table IX.—Cases of cancer during use of oral contraceptives

Reference	Compound	Number of women	Total cycles studied	Number of cases of cancer observed during treatment	
		treated		Genital	Mammary
Pincus, 1959	Enovid	830	8, 133	0	0
Cook et al., 1961	do	550	6, 743	2	0
Pincus, 1961	do		20, 442	1	0
Goldzieher et al., 1962	Enovid, Ortho-Novum	1, 004 210	1 33, 132 6, 232	(²)	0
Rice-Wray et al., 1962	Ortho-Novum	364	6, 062	0	0
Rice-Wray et al., 1963	Enovid, Ortho-Novum	2, 040	* 22, 948	0	ŏ

Table X.—The rate of development of suspicious Papanicolaou smears in subjects with negative smears before the use of contraceptives

Contraceptive used		Number/1,000 with suspicious smears	Average number of years of use	
Vaginal	208 580 188 105 500	72. 1±18. 0 1 26. 2± 6. 6 21. 3±10. 5 28. 6±16. 4 54. 0±10. 0	1. 3 3. 4 1. 8 1. 6 1. 1	

¹ Italic values differ significantly from those for vaginal contraceptives.

Number not stated;
 Number not stated; smear taken at annual pelvic examinations.
 Enovid and Ortho-Novum used in 85 percent of cycles.

⁴ Data of Lee, for Puerto Rico.

Calculated on basis of 31 months average duration of treatment.

Calculated on basis of 31 months average duration of treatment.
 No cases reported based on physical examination, pelvic or biopsy.

^{*} Enovid or Ortho-Novum employed in about 85 percent of cycles.

From data submitted by Dr. Gregory Pincus (Jan. 6, 1966).